Level 1 — Absolute Beginner

Many people in the world have high blood pressure. This is sometimes called hypertension. It can make people very sick if they do not treat it.

Doctors give medicine to lower blood pressure. But some people take a lot of pills and the pressure is still high.

On May 18, 2026, a U.S. health office called the FDA said yes to a new pill. The pill is called Baxfendy. The company that makes it is AstraZeneca.

The new pill works in a different way from old pills. In big tests, it made the blood pressure go down even for people who took other medicines first. Doctors hope it will help millions of people.

blood pressure

the force of blood pushing on the walls of your blood vessels

high blood pressure

blood pressure that is too strong and can harm your body over time

medicine

a substance that you take to treat an illness

pill

a small round piece of medicine that you swallow

doctor

a person trained to look after people who are sick

FDA

the United States Food and Drug Administration, which decides if a new medicine is safe to sell

company

a business that makes or sells things

test

a careful study to see if something works or is safe

Level 2 — Elementary

On May 18, 2026, the United States Food and Drug Administration approved a new medicine called Baxfendy. The chemical name is baxdrostat. AstraZeneca, a British-Swedish drugmaker, will sell it in the United States as a once-a-day tablet.

Baxfendy is the first medicine of a new type called an aldosterone synthase inhibitor. The body makes a hormone called aldosterone that tells the kidneys to keep more salt and water. Too much aldosterone pushes blood pressure higher. Baxfendy blocks the enzyme that makes aldosterone, so the body produces less of it.

The FDA approved Baxfendy as an extra treatment for adults who already take other blood-pressure pills but whose pressure is still too high. Doctors call this 'resistant hypertension.' About one in five adults with high blood pressure has this difficult form, and it raises the risk of stroke, heart attack and kidney failure.

In the company's main study programme — known as BaxHTN — about 22,000 patients took part. People who added a 2-milligram daily dose of baxdrostat to their usual medicines saw their top blood-pressure number fall by almost 10 mmHg more than those who took a placebo. Side effects were similar to placebo overall, though about 1 in 50 patients had higher potassium levels and needed monitoring.

approve

to officially agree that something can happen or be used

tablet

a small flat piece of medicine to be swallowed

hormone

a chemical that the body makes to send messages between organs

kidney

one of two organs in the body that clean the blood and make urine

enzyme

a protein that speeds up a chemical reaction in the body

resistant hypertension

high blood pressure that stays high even when a person takes several different medicines

placebo

a dummy treatment with no active medicine, used in tests to compare with the real medicine

side effect

an extra and often unwanted effect that a medicine causes besides its main effect

Level 3 — Intermediate

The U.S. Food and Drug Administration on May 18, 2026 granted full approval to baxdrostat, an oral, once-daily, highly selective small-molecule inhibitor of aldosterone synthase, under the brand name Baxfendy. AstraZeneca, which acquired the asset from CinCor Pharma for roughly 1.8 billion dollars in 2023, will launch the 1-mg and 2-mg tablets in the United States in June, with European Medicines Agency action expected in the third quarter of 2026.

Baxfendy is the first agent of its class to reach any major regulator. Conventional 'mineralocorticoid receptor antagonists' such as spironolactone and eplerenone block the downstream receptor on which aldosterone acts, but tolerability is limited by gynaecomastia, hyperkalaemia and sexual side effects. Baxdrostat instead inhibits CYP11B2, the cytochrome-P450 enzyme that catalyses the final step of aldosterone biosynthesis in the adrenal cortex, with a roughly 100-fold selectivity over the structurally similar CYP11B1 enzyme that produces cortisol. Selectively suppressing aldosterone production without compromising cortisol output is the long-sought biochemical objective that has eluded earlier candidates.

Approval rests on the BaxHTN, BaxHTN-OL and BaxResist programme — roughly 22,000 patients across phase II and phase III trials — in which 2-mg daily baxdrostat layered on top of background therapy lowered seated systolic blood pressure by an additional 9.8 mmHg at twelve weeks versus placebo in patients with treatment-resistant hypertension already on three or more antihypertensive medications including a diuretic. Diastolic pressure fell by an additional 4.6 mmHg. The benefit was preserved in BaxHTN-OL out to fifty-two weeks and was numerically larger in self-identified Black participants, who carry a disproportionate burden of resistant hypertension in the United States.

The FDA label warns of hyperkalaemia, requiring serum-potassium monitoring at week two and week six, and reduced dosing in stage-4 chronic kidney disease. Adrenal-insufficiency risk is judged low given the preserved cortisol output. Wall Street analysts model peak Baxfendy sales at 5–7 billion dollars annually by 2031, with the obvious upside hinging on outcome data from the in-flight BaxOUTCOMES trial that randomises 14,000 high-risk patients to baxdrostat versus placebo for cardiovascular events through 2028. AstraZeneca's shares closed up 4.1% on the London Stock Exchange on the day of approval.

aldosterone synthase

the adrenal-cortex enzyme that catalyses the final biosynthetic step from corticosterone to aldosterone

mineralocorticoid receptor antagonist

a drug class that blocks the receptor on which aldosterone acts, including spironolactone and eplerenone

CYP11B2

the cytochrome-P450 11B2 enzyme responsible for aldosterone synthesis; the molecular target of baxdrostat

CYP11B1

the structurally similar enzyme responsible for cortisol synthesis; selectivity over CYP11B1 is critical for adrenal safety

Level 4 — Advanced

The U.S. Food and Drug Administration on May 18, 2026 granted standard approval to baxdrostat, an orally bioavailable, highly selective small-molecule inhibitor of CYP11B2 — the rate-limiting aldosterone synthase enzyme — under the trade name Baxfendy. The label clears once-daily 1-mg and 2-mg tablets as add-on therapy in adults with uncontrolled or treatment-resistant hypertension already managed on optimised background regimens that include a renin–angiotensin–aldosterone-system blocker, a calcium-channel blocker and a thiazide-type diuretic. AstraZeneca, which originated the asset commercially through its 2023 acquisition of CinCor Pharma at $26 per share (roughly 1.8 billion dollars, with up to $500 million in regulatory contingent-value rights), confirmed a U.S. wholesale acquisition cost of $14.80 per tablet at launch in mid-June.

Baxdrostat occupies a regulatory niche that has resisted pharmacological attack for half a century. Conventional mineralocorticoid-receptor antagonists — spironolactone (1959), eplerenone (2002) and finerenone (2021) — operate downstream by blocking the renal-tubular and cardiovascular receptors on which aldosterone acts; their use is constrained by gynaecomastia and hyperkalaemia (spironolactone), and by costlier on-treatment monitoring (finerenone). Baxdrostat instead acts upstream, inhibiting the cytochrome-P450 11B2 enzyme that catalyses the final 11-β-hydroxylation and 18-oxidation steps converting corticosterone to aldosterone within the zona glomerulosa of the adrenal cortex. The medicinal-chemistry feat that distinguished it from prior class entrants (notably osilodrostat and dexfenfluramine derivatives) was achieving a roughly 100-fold in vitro selectivity over the structurally near-identical CYP11B1 enzyme responsible for cortisol synthesis — preserving glucocorticoid output and obviating the need for steroid replacement.

Approval rests on an integrated 22,000-patient programme spanning BaxHTN (phase II, NCT05432050), BaxHTN-OL (52-week open-label extension), BaxResist (phase III in treatment-resistant hypertension) and a Japanese-population bridging study. The pre-specified primary endpoint — change from baseline in mean seated automated office systolic blood pressure at twelve weeks versus placebo — showed a placebo-adjusted reduction of 9.8 mmHg with 2 mg/day baxdrostat and 7.4 mmHg with 1 mg/day, sustained at 52 weeks in BaxHTN-OL and numerically larger (11.6 mmHg) in pre-specified analyses of self-identified Black participants, a population in which resistant hypertension exhibits both higher prevalence and disproportionate target-organ damage. Diastolic pressure fell by an additional 4.6 mmHg; ambulatory blood-pressure-monitoring substudies confirmed maintenance of nocturnal dipping pattern.

The FDA Prescribing Information carries a section-5.1 warning for hyperkalaemia, requiring serum-potassium measurement at week 2 and week 6 with dose-down or interruption at K+ ≥ 5.5 mEq/L; renal-dose adjustment to 1 mg in stage-4 chronic kidney disease (eGFR 15–29 mL/min/1.73 m²); and a section-7 contraindication with concomitant strong CYP3A4 inhibitors such as ketoconazole. Adrenal-insufficiency risk was judged low — ACTH-stimulation testing across the development programme showed preserved cortisol response — and no signal of QTc prolongation was observed at four-times the therapeutic exposure in dedicated thorough-QT assessment. Sell-side analysts at JP Morgan, Goldman Sachs and Jefferies model peak Baxfendy net sales of $5–7 billion annually by 2031, with the substantive upside contingent on read-out of the in-flight BaxOUTCOMES trial (NCT06108823) — a 14,000-patient event-driven randomised trial assessing the composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and heart-failure hospitalisation through Q4 2028. AstraZeneca's London-listed shares closed up 4.1% on the day of approval, lifting the company's market capitalisation past 230 billion pounds.